论文部分内容阅读
[目的]探讨沉默SALL4基因对乳腺癌耐药细胞MCF-7/A的增殖及化疗敏感性的影响。[方法]q RT-PCR和Western Blot实验检测MCF-7、MCF-7/A细胞内SALL4表达水平,运用慢病毒包装sh RNA方法沉默MCF-7/A细胞的SALL4基因;实验组(Lv-sh SALL4)、阴性对照组(Lv-sh NC)和空白对照组(CON)。CCK8法、克隆形成实验检测SALL4沉默对细胞增殖能力的影响;CCK8法检测表柔比星处理细胞24h和48h的半数抑制浓度(IC_(50));流式细胞仪检测细胞凋亡。[结果]SALL4在MCF-7/A细胞中的表达水平显著高于MCF-7(P<0.05)。MCF-7/A细胞中SALL4基因被成功沉默,病毒感染MCF-7/A细胞72h后,细胞感染效率约95%,沉默SALL4基因后MCF-7/A细胞内SALL4 m RNA及蛋白表达均明显降低(P<0.05)。沉默MCF-7/A细胞的SALL4基因,显著抑制了细胞的增殖能力(P<0.05),增强了细胞对表柔比星的敏感性;表柔比星24h和48h的IC_(50)均明显降低(P<0.05),并且表柔比星诱导的细胞凋亡增加(P<0.05)。[结论 ]沉默SALL4基因能够抑制乳腺癌耐药细胞MCF-7/A的增殖,增强耐药细胞对表柔比星的敏感性。SALL4基因沉默可能是乳腺癌治疗的新靶点。
[Objective] To investigate the effect of silencing SALL4 gene on the proliferation and chemosensitivity of breast cancer cell line MCF-7 / A. [Methods] The expression of SALL4 in MCF-7 and MCF-7 / A cells was detected by RT-PCR and Western Blot. The SALL4 gene in MCF-7 / A cells was silenced by lentivirus packaging sh RNA. sh SALL4), negative control group (Lv-sh NC) and blank control group (CON). CCK8 assay was used to detect the effect of SALL4 silencing on cell proliferation. CCK8 assay was used to detect the IC50 of IC50 for 24h and 48h after treatment with epirubicin. Cell apoptosis was detected by flow cytometry. [Results] The expression of SALL4 in MCF-7 / A cells was significantly higher than that in MCF-7 (P <0.05). The SALL4 gene was successfully silenced in MCF-7 / A cells. The virus infection efficiency of MCF-7 / A cells was about 95% after 72 h. The SALL4 mRNA and protein expression in MCF-7 / A cells were significantly decreased after SALL4 silencing Decreased (P <0.05). The silencing of SALL4 gene in MCF-7 / A cells significantly inhibited the proliferation of cells (P <0.05), and enhanced the sensitivity of cells to epirubicin. IC 50 of epirubicin 24h and 48h were significantly (P <0.05), and the apoptosis induced by epirubicin increased (P <0.05). [Conclusion] SALL4 silencing can inhibit the proliferation of MCF-7 / A breast cancer cells and enhance the sensitivity of drug-resistant cells to epirubicin. SALL4 gene silencing may be a new target for the treatment of breast cancer.